Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study

Journal of Heart and Lung Transplantation

Volumn 35, Issue 11, 2016, Pages 1370-1373

  Finch, Kimberly T ^a   Stratton, Eric A ^a   Farber, Harrison W ^b  

^a Arthritis Center   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; CARDIOVASCULAR AGENT;

ADULT; BODY MASS; BORG DYSPNEA INDEX; BRADYCARDIA; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LETTER; LUNG ARTERY PRESSURE; MALE; MORTALITY; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; AGED; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; CARDIOVASCULAR AGENTS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MALE; PILOT PROJECTS; RANOLAZINE; STROKE VOLUME;

EID: 84992747462     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.07.015     Document Type: Letter

References (7)

1. 1 Hussain, N., Charalampopoulos, A., Ramjug, S., et al. Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ 6 (2016), 3–14.
2. 2 Rosenkranz, S., Gibbs, J.S., Wachter, R., DeMarco, T., Vonk-Noordegraaf, A., Vachiery, J.L., Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37 (2016), 942–954.
3. 3 Guazzi, M., Gomberg-Maitland, M., Arena, R., Pulmonary hypertension in heart failure with preserved ejection fraction. J Heart Lung Transplant 34 (2015), 273–281.
4. 4 Tannenbaum, S., Sayer, G.T., Advances in pathophysiology and treatment of heart failure with preserved ejection fraction. Curr Opin Cardiol 30 (2015), 250–258.
5. 5 Rayner-Hartley, E., Sedlak, T., Ranolazine: a contemporary review. J Am Heart Assoc, 5, 2016, e003196.
6. 6 Mihos, C.G., Krishna, R.K., Kherada, N., Larrauri-Reyes, M., Tolentino, A., Santana, O., The use of ranolazine in non-anginal cardiovascular disorders: a review of current data and ongoing randomized clinical trials. Pharmacol Res 103 (2016), 49–55.
7. 7 Maier, L.S., Layug, B., Karwatowska-Prokopczuk, E., et al. RAnolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 1 (2013), 115–122.